![[ Visit Client Website ]](images/banner.gif)
Learning Objectives
At the conclusion of this presentation attendees will be able to:
- Recognize that smoking cessation rates are greater among those using FDA-approved stop-smoking medication in the population setting. Recognize the need to account for differential recall of unsuccessful quit attempts among medication users and non-users when relying on retrospective survey designs to assess medication effectiveness.
Key Points: Use of stop-smoking medication in the population setting is associated with increased quit rates compared to quit rates among those attempting to quit without medication. Sustained abstinence rates are highest among those using varenicline. Differential recall of past quit attempts, with decreased recall of failed unassisted attempts, provides an additional explanation for the failure of previous population-based studies to consistently show a benefit of using stop-smoking medications. The present findings were established using a prospective cohort survey design. Participants were 7,436 adult smokers (18+ years) from the United Kingdom, Canada, Australia, and the United States, who were interviewed as part of the International Tobacco Control Four Country Survey (ITC-4) between 2002 and 2009.
Educational Experience: The audience will interpret the odds of sustained abstinence from smoking as a function of medication use, stratified by recalled quit attempt recency.
Benefits: The audience will be able to use their knowledge of the real-world effectiveness of stop-smoking medications to inform decisions regarding the promotion of FDA-approved cessation medications.